Anavex Life Sciences (Anavex Life Sciences) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Anavex Life Sciences LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Anavex Life Sciences's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.00.

Anavex Life Sciences's long-term debt to total assets ratio stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00).

Anavex Life Sciences LT-Debt-to-Total-Asset Historical Data

The historical data trend for Anavex Life Sciences's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anavex Life Sciences LT-Debt-to-Total-Asset Chart

Anavex Life Sciences Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

Anavex Life Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Anavex Life Sciences LT-Debt-to-Total-Asset Calculation

Anavex Life Sciences's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Sep. 2023 is calculated as

LT Debt to Total Assets (A: Sep. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Sep. 2023 )	/	Total Assets (A: Sep. 2023 )
	=	0	/	154.386
	=

Anavex Life Sciences's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	0	/	148.07
	=

Anavex Life Sciences (NAS:AVXL) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Anavex Life Sciences LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Anavex Life Sciences's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Anavex Life Sciences (Anavex Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anavex Life Sciences Corp (NAS:AVXL) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

12X1:Germany 12X1:Germany

Address

630 5th Avenue, 20th Floor, New York, NY, USA, 10111

Website

https://www.anavex.com

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.

Executives

Christopher U Missling	director, officer: President, CEO, CFO, Treasurer, other: Secretary	61 MOULTON ST, CAMBRIDGE MA 02138
Athanasios Skarpelos	10 percent owner	14,RUE KLEBERG, GENEVA V8 CH-1201
Jiong Ma	director	445 PARK AVENUE, 9TH FLOOR, NEW YORK NY 10022
Elliot Favus	director	51 W 52ND STREET, 7TH FLOOR, NEW YORK NY 10091
Donhauser Peter D.o.	director	REGINA-KIRCHMAIER STRASSE 4, KAUFBEUREN 2M 87600
Sandra Boenisch	officer: PFO & Treasurer	51 WEST 52ND STREET, 7TH FLOOR, NEW YORK NY 10019
Claus Vander Velden	director	PO BOX MUENSTEREIFELER ST., COLOGNE 2M 50937
Steffen Thomas	director	FALLMERAYER STR. 19, MUNICH 2M 80796
Bernd Metzner	director	51 W 52ND STREET, 7TH FLOOR, NEW YORK NY 10019
George F Tidmarsh	director, officer: Executive Director
John Robert Chisholm	director	16308 36A AVENUE, SURREY A1 V3S 0X5
William Sean Lowry	director	1172 BAY STREET, SUITE 300, ONTARIO Z4 M5S1L9
David L. Tousley	director	14610 PAWNEE LANE, LEAWOOD KS 66224
Harvey Lalach	director, officer: President CEO CFO	4837 CANYON RIDGE CRESENT, KELOWNA A1 V1W 4A1
Alison E. Ayers	director	27 O'CONNOR CIRCLE, WEST ORANGE NJ 07052